... Shionogi joined as a 10% shareholder in October 2012. The company's aim is to take a deeper and broader interest in HIV/AIDS than any company has done before and take a new approach to deliver effective and new HIV medicines, as well as support ...
http://www.pressreleasepoint.com/viiv-healthcare-announces-european-regulatory-submission-single-tablet-regimen-combining-dolutegravi
http://www.pressreleasepoint.com/viiv-healthcare-announces-european-regulatory-submission-single-tablet-regimen-combining-dolutegravi
No comments:
Post a Comment